Epigenetic Nucleosomes in Plasma for Pulmonary Nodule Differentiation

Last updated: May 12, 2025
Sponsor: National Taiwan University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pulmonary Nodules

Treatment

blood draw

Clinical Study ID

NCT06838806
202412107RIND
  • Ages > 20
  • All Genders

Study Summary

We aim to evaluate the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population and compare its diagnostic performance with low-dose computed tomography (LDCT) or computed tomography (CT). Additionally, we will investigate the potential role of Nu.Q in lung cancer prevention and its impact on survival outcomes.

Study Method:

We plan to collect 20 mL of blood samples from individuals undergoing chest LDCT/CT, isolate plasma for Nu.Q™ analysis, and compare the results with corresponding lung cancer pathology findings. The estimated sample size is 500 participants.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged 20 or older

  • Underwent a low-dose chest CT scan or a standard chest CT scan, showing lung nodules ≥ 6mm

  • Individuals understand the content of the consent form and are willing toparticipate in this study.

  • The lung nodule is assessed by a physician as high-risk, requiring thoracic surgeryor biopsy for diagnosis

Exclusion

Exclusion Criteria:

  • Pregnant women

  • Individuals without capacity for consent, unable to understand the content of theconsent form, or unwilling to participate in this study

  • Assessed by a physician as unsuitable for thoracic surgery or biopsy for diagnosis

Study Design

Total Participants: 500
Treatment Group(s): 1
Primary Treatment: blood draw
Phase:
Study Start date:
March 11, 2025
Estimated Completion Date:
February 28, 2026

Study Description

Currently, early lung cancer screening primarily relies on low-dose computed tomography (LDCT) of the chest. However, blood tests offer a more convenient alternative. Despite this, existing blood tests lack sufficient accuracy and sensitivity for lung cancer screening. Developing a reliable blood-based screening tool could significantly enhance the detection rate and accuracy of early lung cancer screening.

Previous studies have shown that nucleosomes undergo variations during early cancer development. The Belgian company Volition has developed a blood test method based on chemiluminescence immunoassay (ChLIA) to measure nucleosomes in the blood, branded as Nu.Q™. Preliminary studies have demonstrated that Nu.Q™ can detect abnormal nucleosome biomarkers associated with early lung cancer.

This study, in collaboration with Volition, will collect 20 mL of blood samples from individuals undergoing chest LDCT. Plasma will be isolated and analyzed using Nu.Q™ at the National Taiwan University Center for Genomics and Precision Medicine. The test results will be compared with corresponding lung cancer medical records, LDCT findings, and pathological diagnoses. The study aims to enroll 500 participants.

The objectives of this study are to validate the diagnostic accuracy of the Nu.Q™ blood test for lung cancer in the Taiwanese population, compare its diagnostic performance with LDCT, and explore its potential role in lung cancer prevention and improved survival outcomes. This study is conducted as an industry-academic collaboration project with National Taiwan University.

Connect with a study center

  • National Taiwan University

    Taipei,
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.